CYP24A1 homozygous gene mutation is a well-known cause of infantile hypercalcemia and adult onset hypercalcemia/nephrocalcinosis. A mutation in this gene causes the loss of function of 24 hydroxylase enzyme that is essential for the catabolism of vitamin D metabolites.
Introduction
The prevalence of vitamin D-mediated hypercalcemia is unknown, but currently increasing due to increase in vitamin D supplementation and increase detection of cytochrome P450 24A1 (CYP24A1) mutations [1] . We present a patient with recurrent nephrolithiasis with hypercalciuria and elevated 1,25-dihydroxyvitamin D3
(1,25-(OH) 2 D 3 ) level without a history of hypercalcemia nor nephrolithiasis during childhood associated with two variants of heterozygous CYP24A1 mutations.
Case Presentation
A 35-year-old man presented with a complaint of recurrent nephrolithiasis. He has significant medical history of multiple episodes of nephrolithiasis since the age of 21 that required multiple laser lithotripsy and ureteral stent placement (stone analysis showed calcium oxalate). He also has a family history of recurrent kidney stone in his The patient was advised against prolonged sun exposure, vitamin D/ calcium supplements and was encouraged to increase oral hydration.
He was started on hydrochlorothiazide 12.5 mg daily which resolved the hypercalciuria without worsening in serum calcium level. His kidney function remained stable without further recurrent kidney stone.
A kidney Ultrasound one year later was negative of stones.
Discussion
We herein report an adult patient with a personal and family history of Whether CYP24A1 mutations may be the only underlying cause in patients with suggestive biochemical profile is currently unknown.
A recent mutation screen of CYP24A1 in two cohorts of renal stone-forming patients from the Northeast of England with biochemical profile suggestive for CYP24A1 deficiency revealed no pathogenic CYP24A1 mutations [8] . Such patients may have pathological variants outside the coding region of CYP24A1 (e.g., in the promoter region) or may have variants in other genes in the same pathway leading to similar pathophysiology, such as activating mutations in cytochrome P450 27B1 (CYP27B1) [9] .
Long-term management of hypercalcemia and hypercalciuria due to inactivating CYP24A1 mutations aim to reduce hypercalciuria and thus nephrocalcinosis/nephrolithiasis. Decreasing calcium and vitamin D intake is sufficient for many patients. A variety of medications could be added if needed like glucocorticoids, loop and thiazide diuretics, phosphate supplementation, proton pump inhibitors and antifungal (ketoconazole and fluconazole) [1, 5] . Thiazide diuretics decrease urine calcium excretion without exacerbation of hypercalcemia in most cases [1] , as was the case in our patient.
In conclusion, CYP24A1 inactivation mutations should be suspected in adults with personal and family history of recurrent nephrolithiasis if they present with non PTH-mediated hypercalcemia and/or hypercalciuria and elevated 1,25-(OH)2D3 level even without a history of hypercalcemia during childhood. Genetic testing and recognition of disease can promote early diagnosis and treatment. Thiazide diuretic may be used for its management safely.
